Hemab Therapeutics Initiates SOLARA, Pivotal Phase 3 Trial Evaluating Sutacimig As Potential Prophylactic Treatment For People With Glanzmann Thrombasthenia
Benzinga Newsdesk 20 hours ago
News
Hemab’s first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombastheniaSingle-arm design with a 24-week run-in followed by 48 weeks of treatment; primary
Hemab’s first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombasthenia
Single-arm design with a 24-week run-in followed by 48 weeks of treatment; primary endpoint is annualized treated bleed rate
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (NASDAQ:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the initiation of SOLARA, a pivotal Phase 3 trial evaluating sutacimig (HMB-001) as a potential prophylactic treatment for people with Glanzmann thrombasthenia (GT). The first participants have been consented and are scheduled to enter the trial's run-in period in the fourth quarter of 2026. GT is a serious, inherited platelet function disorder for which no prophylactic therapy is currently approved. Sutacimig is an investigational, once-weekly subcutaneous bispecific antibody designed to help form stable hemostatic plugs at the site of bleeding, compensating for platelet dysfunction.